What is XORTX Therapeutics Inc?
, a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
, a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 2.00M.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.